Article History

Accepted: 17 August 2023

First Online: 4 October 2023

Change Date: 27 October 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s11523-023-01010-3

Change Date: 9 December 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s11523-023-01020-1

Declarations

:

: Medical writing support for the development of this podcast manuscript, under the direction of the authors, was provided by Jim Sinclair, PhD, of Ashfield MedComms, an Inizio Company, and was funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). BIPI was given the opportunity to review the podcast manuscript for medical and scientific accuracy as well as intellectual property considerations.

: Xiuning Le has received consultant and advisory fees from AstraZeneca, BluePrint Medicine, Boehringer Ingelheim, Daiishi Sanko, Eli Lilly, EMD Serono, Hengrui Therapeutics, Janssen, Spectrum Therapeutics, and Novartis; and research funding from Arrivent, Eli Lilly, Boehringer Ingelheim, Teliegen, and Spectrum Pharmaceuticals. Eric Nadler has received payment for speaker bureau and speaker arrangement from Merck, AstraZeneca, Genentech, G1 Therapeutics, Jazz Pharmaceuticals, and Blueprint Pharma. Daniel B. Costa has received personal fees (consulting fees and honoraria) from AstraZeneca, BluePrint Medicine, Janssen, Pfizer, and Takeda/Millennium Pharmaceuticals; consulting fees from Teladoc and Grand Rounds by Included Health; and nonfinancial support (institutional research support) from AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Daiichi Sankyo, Merck Sharp and Dohme Corporation, Merrimack Pharmaceuticals, Pfizer, Spectrum Pharmaceuticals, Takeda/Millennium Pharmaceuticals, and Tesaro. John Victor Heymach has received research support from AstraZeneca, Boehringer Ingelheim, Spectrum, and Takeda; holds an advisory role with AstraZeneca, BMS, BrightPath Biotherapeutics, Chugai Pharmaceuticals, EMD Serono, Boehringer Ingelheim, Catalyst, Eli Lilly, Genentech, GlaxoSmithKline, Hengrui Therapeutics, Janssen Global Services, Mirati Therapeutics, Nexus Health Systems, Pneuma Respiratory, RefleXion, Spectrum, Sanofi, and Takeda; and has received royalties and licensing fees from Spectrum.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: The authors met the criteria for authorship as recommended by the International Committee of Medical Journal Editors.

: No datasets were generated or analyzed during the current study.